US-based Leonard Hair Transplant Associates (LHTA) has received approval from the US Food and Drug Administration (FDA) for its Capillus272 low-level laser therapy device to treat androgenic alopecia (male and female pattern hair loss).
The Capillus272 is a mobile and battery-operated laser product, which fits within a baseball cap for unnoticed and private use, noted LHTA.
The FDA clearance for Capillus272 was based on an independently reviewed clinical study, and it is indicated to treat both men and women.
LHTA founder and chief surgeon Dr Robert Leonard said: "At LHTA, we have treated more than 6,000 patients with this therapeutic method – more than any other hair restoration practice in the nation."
The device has been exclusively offered by the company in its Massachusetts, Rhode Island and New Hampshire offices for the past three years, and is the only medical hair-loss practice to provide the Capillus272 to patients in New England.
The company provides hair restoration surgery and medical treatments, including Artas Robotic System, NeoGraft, Capillus Laser Cap, and Propecia, as well as hair transplantation.